Clinigen

86 articles about Clinigen

• Clinigen launches NaviGATE: an educational programme for rare disease patients and organisations

  9/12/2023

  Clinigen, the global pharmaceutical services company, announces the launch of NaviGATE, a UK-based pilot educational programme for rare disease patient advocates and organisations.

• Clinigen divests global rights to four cancer support therapies to CNX Therapeutics

  8/10/2023

  Clinigen Limited, the global pharmaceutical services company, has completed the divestment of four cancer supportive care products from its established brands portfolio to CNX Therapeutics, a speciality pharmaceutical company with a focus on improving access to medicines that are critical to the well-being of patients.

• Clinigen divests Proleukin® to Iovance Biotherapeutics for £166.7 million

  1/23/2023

  Clinigen Limited (‘Clinigen’) (‘the Company’), the global pharmaceutical services company, has entered into an agreement to divest Proleukin® (interleukin-2 (aldesleukin)), to Iovance Biotherapeutics, Inc.

• Clinigen notes results from the MIROCALS trial investigating low dose Proleukin® (aldesleukin) in patients with amyotrophic lateral sclerosis

  12/8/2022

  Clinigen Limited is pleased to notethe announcement of top-line results from MIROCALS a phase 2b randomised placebo-controlled trial investigating the efficacy and safety of low dose interleukin-2 for controlling neuro-inflammation in newly-diagnosed patients with amyotrophic lateral sclerosis.

• Clinigen adds pharmacovigilance capabilities with acquisition of Drug Safety Navigator

  11/29/2022

  Clinigen Limited, the global pharmaceutical services company, has agreed to acquire Drug Safety Navigator Inc., a specialist pharmacovigilance service provider based in the US.

• Clinigen expands US site capacity in response to growing demand for Clinical Supplies Management services

  5/24/2022

  Clinigen Limited, the global pharmaceutical services company, announces it has nearly doubled its US site capacity to better service large-scale clinical trials.

• Clinigen Expands Partnership With Accord Healthcare in Clinical Services Into France

  11/24/2020

    Expands operations of exclusive ‘on-demand’ supply service beyond the UK into France Enables continuity of supply for global clinical trial customers wanting EU product Long term partnerships between Accord Healthcare and both Clinical Services and Global Access, demonstrating strong position serving both pharma and HCPs’ needs

• Xeris Pharmaceuticals Signs Exclusive Agreement With Clinigen to Supply and Distribute Gvoke™ Outside the U.S on a Named Patient Basis

  5/14/2020

  Xeris Pharmaceuticals, Inc. announced an exclusive agreement with Clinigen Group plc to manage the supply and distribution of Gvoke™ outside of the United States where Gvoke is not currently licensed.

• Clinigen Signs Exclusive Agreement with Xeris Pharmaceuticals to Supply and Distribute Gvoke™ Outside the US

  5/14/2020

  Clinigen Group plc, the global pharmaceutical and services company, has signed an exclusive agreement with Xeris Pharmaceuticals, Inc. to manage the supply and distribution of Gvoke™ injection, a treatment for diabetes, outside the US.

• Clinigen: IL-2 Plays Role in Emerging TIL Therapies

  5/4/2020

  Clinigen Group plc, the global pharmaceutical and services company acknowledges the presentation of results from the Phase I trial “Durable complete responses to adoptive cell transfer using tumor infiltrating lymphocytes in non -small cell lung cancer.” Ben C. Creelan MD, MS from the Thoracic Oncology, Immunology Program of the Moffitt Cancer and Research Institute presented at the American Association for Cancer Research virtual annual meeting on April 28, 2020.

• Clinigen signs agreement with Iovance Biotherapeutics to supply Proleukin® (aldesleukin) for use in Tumor Infiltrating Lymphocyte (TIL) Clinical R&D

  1/15/2020

  Proleukin is the first and only FDA approved IL-2 being used in development of T-Cell treatments

•  Clinigen and Orphazyme launch an Early Access Program for arimoclomol in patients with Niemann-Pick disease type C

  1/6/2020

  Clinigen Group plc has partnered with Orphazyme A/S, a global biopharmaceutical company dedicated to developing treatments for patients living with rare diseases, to introduce and administer an Early Access Program for arimoclomol in patients with Niemann-Pick disease type C in the US.

• 

  BioSpace Global Roundup, Oct. 17

  10/17/2019

  Companies from across the globe provide business and pipeline updates.

• Clinigen launches Managed Access Program for Progenics Pharmaceuticals for AZEDRA® outside the US

  10/15/2019

  Clinigen Group plc has launched a Managed Access Program for Progenics Pharmaceuticals, Inc., an oncology company developing innovative targeted medicines and artificial intelligence to find, fight and follow cancer, to provide AZEDRA® via a global Managed Access Program, outside the United States.

• Clinigen Launches Managed Access Program for Progenics Pharmaceuticals for AZEDRA® Outside the US

  10/10/2019

  AZEDRA is not approved for use outside of the United States.

• Transformational year - platform taking shape to support higher organic growth

  9/24/2019

  Clinigen Group plc, the global pharmaceuticals and services group, has published its full year results for the year ended 30 June 2019.

• 

  BioSpace Global Roundup: June 27

  6/27/2019

  Biotech and pharma companies from across the globe share pipeline and business updates.

• Clinigen - MHRA licenses two Melatonin products indicated for short-term jet-lag treatment in adults

  6/26/2019

  Obtaining marketing authorisations for a previously unlicensed product is an example of the unlicensed to licensed strategy in the Commercial Medicines business and follows the successful launch of previous products in the portfolio, including Glycopyrronium Bromide Oral Solution.

• Clinigen broadens partnership with Accord Healthcare to supply and distribute Cardioxane® and Savene® in Poland

  6/24/2019

  Cardioxane is used as a cardio protectant with cancer chemotherapy treatment.

• 

  BioSpace Movers and Shakers: May 3

  5/3/2019

  Biopharma companies make changes to their C-suite leadership teams, with hires at uBiome, Enzyre, Sobi, Amylyx, Mission Therapeutics, and more.